Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants

Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates

“…The authors of the 2006 reviews separated Epo studies into early (first week of life) and late (after the first week) administration, and concluded that the incidence of ≥stage 3 ROP was increased with early Epo administration. Only 1 study in this meta-analysis reported an increase in ROP among recipients of Epo, a single-center study by Romagnoli et al 14 In revised meta-analyses 15,16 of the 27 studies randomizing 2209 infants to early Epo or placebo, the incidence of ROP was reported in 7 studies, comprising only 36% of all study infants. Despite their initial report in 2000, Romagnoli et al continued to study Epo, 17 and Epo is currently standard of care in their unit.…”

Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates

“…The authors of the 2006 reviews separated Epo studies into early (first week of life) and late (after the first week) administration, and concluded that the incidence of ≥stage 3 ROP was increased with early Epo administration. Only 1 study in this meta-analysis reported an increase in ROP among recipients of Epo, a single-center study by Romagnoli et al 14 In revised meta-analyses 15,16 of the 27 studies randomizing 2209 infants to early Epo or placebo, the incidence of ROP was reported in 7 studies, comprising only 36% of all study infants. Despite their initial report in 2000, Romagnoli et al continued to study Epo, 17 and Epo is currently standard of care in their unit.…”

Effect of Early Erythropoietin on Retinopathy of Prematurity: A Stratified Meta-Analysis

“…The results of the present meta-analysis should be embedded in the context of previous work. In 2014, the authors of the Cochrane meta-analysis performed a post hoc analysis including all studies that reported on ROP stage ≥3 including early and late initiation of treatment, and there was an increased risk of ROP in the rhEPO group [[3], [35]]. Subsequently, Fang et al [[10]] and Chou et al [[11]] could not replicate this association in their meta-analyses on the effect of early or late rhEPO on ROP.…”

Early predictors of neonatal intraventricular hemorrhage

“…Its incidence increases with decreasing gestational age and birth weight ( 14 ). Maternal EPO does not cross the placenta in pregnancy meanwhile, its elevations in cord blood levels are related to fetal production and by primary production sites; the kidney and fetal liver ( 15 ). The results of the present study showed that group 1 had significantly lower APGAR scores at 1 and 5 minutes than group 2, and this comes in agreement with the study of Riskin A., et al ( 16 ) and Badiee Z.…”

Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates

“…The authors of the 2006 reviews separated Epo studies into early (first week of life) and late (after the first week) administration, and concluded that the incidence of ≥stage 3 ROP was increased with early Epo administration. Only 1 study in this meta-analysis reported an increase in ROP among recipients of Epo, a single-center study by Romagnoli et al 14 In revised meta-analyses 15,16 of the 27 studies randomizing 2209 infants to early Epo or placebo, the incidence of ROP was reported in 7 studies, comprising only 36% of all study infants. Despite their initial report in 2000, Romagnoli et al continued to study Epo, 17 and Epo is currently standard of care in their unit.…”

Effect of Early Erythropoietin on Retinopathy of Prematurity: A Stratified Meta-Analysis

“…The results of the present meta-analysis should be embedded in the context of previous work. In 2014, the authors of the Cochrane meta-analysis performed a post hoc analysis including all studies that reported on ROP stage ≥3 including early and late initiation of treatment, and there was an increased risk of ROP in the rhEPO group [[3], [35]]. Subsequently, Fang et al [[10]] and Chou et al [[11]] could not replicate this association in their meta-analyses on the effect of early or late rhEPO on ROP.…”

Early predictors of neonatal intraventricular hemorrhage

“…Its incidence increases with decreasing gestational age and birth weight ( 14 ). Maternal EPO does not cross the placenta in pregnancy meanwhile, its elevations in cord blood levels are related to fetal production and by primary production sites; the kidney and fetal liver ( 15 ). The results of the present study showed that group 1 had significantly lower APGAR scores at 1 and 5 minutes than group 2, and this comes in agreement with the study of Riskin A., et al ( 16 ) and Badiee Z.…”

Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates

“…The authors of the 2006 reviews separated Epo studies into early (first week of life) and late (after the first week) administration, and concluded that the incidence of ≥stage 3 ROP was increased with early Epo administration. Only 1 study in this meta-analysis reported an increase in ROP among recipients of Epo, a single-center study by Romagnoli et al 14 In revised meta-analyses 15,16 of the 27 studies randomizing 2209 infants to early Epo or placebo, the incidence of ROP was reported in 7 studies, comprising only 36% of all study infants. Despite their initial report in 2000, Romagnoli et al continued to study Epo, 17 and Epo is currently standard of care in their unit.…”

Effect of Early Erythropoietin on Retinopathy of Prematurity: A Stratified Meta-Analysis

“…The results of the present meta-analysis should be embedded in the context of previous work. In 2014, the authors of the Cochrane meta-analysis performed a post hoc analysis including all studies that reported on ROP stage ≥3 including early and late initiation of treatment, and there was an increased risk of ROP in the rhEPO group [[3], [35]]. Subsequently, Fang et al [[10]] and Chou et al [[11]] could not replicate this association in their meta-analyses on the effect of early or late rhEPO on ROP.…”

Early predictors of neonatal intraventricular hemorrhage

“…Its incidence increases with decreasing gestational age and birth weight ( 14 ). Maternal EPO does not cross the placenta in pregnancy meanwhile, its elevations in cord blood levels are related to fetal production and by primary production sites; the kidney and fetal liver ( 15 ). The results of the present study showed that group 1 had significantly lower APGAR scores at 1 and 5 minutes than group 2, and this comes in agreement with the study of Riskin A., et al ( 16 ) and Badiee Z.…”